Showing 3041-3050 of 4878 results for "".
Your MIPS 2018 Reporting Cheat Sheet
https://practicaldermatology.com/topics/practice-management/your-mips-2018-reporting-cheat-sheet/20478/Follow this advice to avoid a penalty in 2020.Navigating Practice: Tips from the DEF Webinar Series
https://practicaldermatology.com/conferences/conference-coverage-def/navigating-practice-tips-from-the-def-webinar-series/23301/From skin signs of COVID-19 to strategies for optimizing telehealth, experts shared strategies to support NPs and PAs.For the record, I forgot to mention…
https://practicaldermatology.com/topics/practice-management/for-the-record-i-forgot-to-mention/20692/Revisiting Hydrotherapy
https://practicaldermatology.com/topics/general-topics/revisiting-hydrotherapy/21028/Cutaneous Manifestations Associated with Nemolizumab
https://practicaldermatology.com/issues/september-2025/cutaneous-manifestations-associated-with-nemolizumab/37628/In the 2025 study by Sasaki et al entitled “Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan,” nemolizumab-induced cutaneous eruptions were found to be relatively common, typically occuPreparing for Private Equity: Benefits and Drawbacks
https://practicaldermatology.com/issues/september-2025/preparing-for-private-equity-benefits-and-drawbacks/37629/Over the past decade, the health care industry has emerged as a prime target for private equity (PE) investment.Who's Afraid of the Big Black Box?
https://practicaldermatology.com/topics/psoriasis/whos-afraid-of-the-big-black-box/20286/New Products
https://practicaldermatology.com/topics/practice-management/new-products/21183/Raising Issues with MOC
https://practicaldermatology.com/topics/practice-management/raising-issues-with-moc/21195/Dermatologists and the AAD speak out against current MOC requirements and suggest changes.The Melanoma Pipeline
https://practicaldermatology.com/topics/skin-cancer-photoprotection/the-melanoma-pipeline/21400/A closer look at the latest data for two investigational agents that have made headlines.